Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
CNS Pharmaceuticals, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
CNSP
Nasdaq
2830
cnspharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment
- Jun 8th, 2026 7:15 am
CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress
- May 20th, 2026 7:02 am
Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6
- May 14th, 2026 9:39 am
CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress
- May 14th, 2026 6:00 am
Top Midday Gainers
- May 4th, 2026 11:59 am
CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing
- May 4th, 2026 5:00 am
CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline
- Mar 11th, 2026 6:35 am
CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team
- Mar 2nd, 2026 6:25 am
CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation
- Feb 17th, 2026 6:25 am
CNS Pharmaceuticals Issues Letter to Shareholders
- Jan 27th, 2026 7:00 am
CNS Pharmaceuticals Announces CEO Transition
- Dec 17th, 2025 5:00 am
CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Nov 17th, 2025 6:35 am
CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting
- Nov 10th, 2025 6:45 am
CNS Pharmaceuticals upgraded to Buy at Maxim on TPI-287 roadmap
- Sep 13th, 2025 7:05 am
CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
- Sep 3rd, 2025 7:15 am
IBN Announces Latest Episode of The BioMedWire Podcast Featuring John Climaco, CEO of CNS Pharmaceuticals Inc.
- Aug 27th, 2025 6:00 am
JTC Team Companies to Present in Webull Corporate Connect Webinar Series: Biotech/MedTech on August 19-21, 2025
- Aug 15th, 2025 8:00 am
CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update
- Aug 15th, 2025 6:05 am
CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
- Aug 14th, 2025 7:15 am
Scroll